KETALAR 50 MG
KETAMINE (KETAMINE HYDROCHLORIDE) : 50 MG · DIN 00224405 · SEARCHLIGHT PHARMA INC
Health Canada status: MARKETED
What is KETALAR?
KETALAR 50 MG contains KETAMINE (KETAMINE HYDROCHLORIDE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 00224405, held by SEARCHLIGHT PHARMA INC, supplied as SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 12-Feb-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is KETALAR used for?
Sole anesthetic for short diagnostic/surgical procedures; induction of anesthesia; supplement to low potency agents like nitrous oxide.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00224405 |
|---|---|
| Brand name | KETALAR |
| Generic / active ingredient | KETAMINE (KETAMINE HYDROCHLORIDE) : 50 MG |
| Manufacturer | SEARCHLIGHT PHARMA INC |
| Strength | 50 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR ; INTRAVENOUS |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N01AX03 KETAMINE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Feb-2024 |
| Original market date | 1971-12-31 00:00:00 |
How is it administered?
Induction: 1-4.5 mg/kg IV (slowly over 60s) or 6.5-13 mg/kg IM. Maintenance: increments of 1/2 to full induction dose as needed. Titrate to patient requirements.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store in original container at room temperature (15°C to 30°C). Protect from light. Discard unused product after operating session.
How is it supplied?
10 mL vials (500 mg) and 20 mL vials (200 mg).
Contraindications
History of CVA; significant hypertension; severe cardiac decompensation; surgery of pharynx/larynx/bronchial tree without muscle relaxants; hypersensitivity to ketamine.
Warnings and precautions
Use only by experienced physicians. Monitor cardiac function. Risk of liver enzyme elevation/fibrosis with chronic use. Increased CSF pressure risk. Potential for drug abuse/dependence.
Is KETAMINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 05 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N01AX03 KETAMINE. 7 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| KETALAR | 10 MG | SOLUTION | SEARCHLIGHT PHARMA INC | MARKETED | DIN 00224391 |
| KETAMINE HYDROCHLORIDE INJECTION USP | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02246795 |
| KETAMINE HYDROCHLORIDE INJECTION USP | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02246796 |
| KETAMINE HYDROCHLORIDE INJECTION, USP | 10 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02550431 |
| KETAMINE HYDROCHLORIDE INJECTION, USP | 50 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02550458 |
| KETAMINE INJECTION, BP | 50 MG | SOLUTION | STERIMAX INC | MARKETED | DIN 02535645 |
| KETAMINE HYDROCHLORIDE INJECTION SDZ | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02387301 |
| KETAMINE HYDROCHLORIDE INJECTION SDZ | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02387336 |
| KETAMINE HYDROCHLORIDE INJECTION SDZ | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02387328 |
| KETAMINE HYDROCHLORIDE INJECTION USP | 100 MG / 2 ML | SOLUTION | STERIMAX INC | APPROVED | DIN 02470934 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.